Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can-Fite BioPharma Ltd.

www.canfite.com

Latest From Can-Fite BioPharma Ltd.

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure

Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.

Research & Development Liver & Hepatic

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial

Pipeline Watch: Phase III Progress With Avelumab, Brimapitide, Inhaled Amikacin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Can-Fite BioPharma Ltd.
  • Senior Management
  • Pnina Fishman, PhD, CEO
    Motti Farbstein, CFO
    Sari Fishman, PhD, Dir., Bus. Dev.
    William D Kerns, VP, Drug Dev.
  • Contact Info
  • Can-Fite BioPharma Ltd.
    Phone: (972) 3 9241114
    10 Bareket St.
    Kiryat Matalon
    P.O. Box 7537 Petah-Tikva, 49170
    Israel
UsernamePublicRestriction

Register